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Midterm follow-up of patients with paroxysmal and persistent atrial
fibrillation after pulmonary vein isolation by cryoballoon ablation
Sarah Traullé, Maciej Kubala, Jean-Sylvain Hermida
CHU sud, Centre d’activité de rythmologie, Amiens, France
Introduction: The objective of this prospective study was to evaluate the
midterm clinical outcomes of PV isolation, using a cryoballoon catheter in our
center.
Methods: Between july 2006 and november 2011, 234 consecutive patients
(age 56±11 years, 76% of men) with symptomatic paroxysmal (n =162) or per-
sistent AF (n =72) underwent PV isolation with a 28 mm or 23 mm cryobal-
loon catheter. In case of AF reccurence, patients could have several
procedures using cryoablation and/or PV isolation and additional linear lesions
by radiofrequency. Follow-up with holter monitoring and phone calls were
performed.
Results: We successfully isolated 713 of 936 PV (76%). In 73 patients
(31%), an irrigated-tip radiofrequency catheter was used to create a supple-
mental focal lesion after cryoapplication and 55 patients (24%) had cavo-
tricuspid isthmus line. 28 mm cryoballoon catheter was mostly used
(141 procedures, 60%).The mean overall procedural duration was 178±36 min
(range 120–285), and mean duration of fluoroscopic exposure was 9±5 min
(range 3–27). Over a median period of 20 months (range 3–53), 12 patients
were lost to follow-up, 4 patients were deceased. At 3 months of follow-up,
78% of patients with paroxysmal AF had remained recurrence free, vs. 69%
of patients with persistent AF. Phrenic nerve palsy was the most frequent,
although reversible complication. A left atrial flutter appeared in 23 cases
(11%). Considering midterm outcomes, 68% of patients with paroxysmal AF
and 62% of patients with persistent AF had no recurrence, after an average of
1.3 procedures. Looking at failures, only 10% of patients did not have any
improvement after ablation. 52% of patients were free of AF without antiar-
rhythmic drugs and 36% of them had stopped anticoagulation. 
Conclusion: PV isolation, using a cryoballoon catheter is a safe and effec-
tive strategy with a high rate of success. It can be an alternative to RF ablation
but randomised comparisons are needed.
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Incidence of atrial fibrillation in patients with atrial flutter before and
after ablation according to the nature of associated heart disease
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Radiofrequency (RF) ablation is a treatment of choice of typical atrial
flutter (AFl). However the risk of atrial fibrillation (AF) is high. Heart disease
(HD) presence may modify this risk. The purpose of the study was to look for
the role of associated HD on previous history of AF and later occurrence of
AF after AFl ablation.
Methods: 965 patients, mean age 64±12, were consecutively referred for
ablation of recurrent or poor-tolerated AFL. Clinical history, occurrence of
AF, data of echocardiography was collected. Patients were followed from
3 months up to 10 years. Antiarrhythmic drugs were stopped after ablation
except in patients with history of AF before ablation.
Results: HD was present in 744 patients (77%): hypertensive disease
(HTD) (n=186), ischemic HD (IHD) (n=163), valvular HD (VHD)
(n=113), dilated cardiomyopathy (DCM) (n= 87), respiratory failure (resp)
(n=84), congenital HD (cong) (n=26), miscellaneous HD (n=59). Prior AF
was more frequent in patients without HD (67%) than in patients with HD
(26%)(p<0.0000). Differences were significant with all subgroups of HD
except for patients with DCM (55%). Last patients differed significantly
from all other subgroups of HD. During follow-up (3±3years) 40 patients
without HD (22%), 115 with HD (18%) developed AF (NS). There were
no differences among all subgroups of HD. Among patients with later AF,
15 without HD (8%); 70 with HD (10%) had no prior AF (NS). Among
subgroups with HD, patients with cong HD had a higher risk of AF
(28.5%) than patients without HD (10%)(p< 0.003) or patients with DCM
(7%) (p<0.01) or HTD (7.5%). Differences were not significant for other
HD’s.
Conclusions: Surprisingly patients without HD had more frequently prior
AF than patients with HD. However after AFl ablation AF risk was similar.
Antiarrhythmic drugs maintained in patients with AF history could have
decreased the risk of subsequent AF. Prior AF was more frequent in patients
with DCM than in patients with other HD. After AFl ablation only patients
with congenital HD seem to have a high risk of developing AF compared to
patients with HD of other origin or patients without HD.
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Discrepancy between antithrombotic therapy and assessed risk of
stroke among patients with atrial fibrillation in French primary care*
Sabouret Pierre, Willems C, Cotte F-E, Depret-Bixio L, Mercier F,
Marie P, Blin P.
Rational : In France around 800,000 patients are diagnosed for atrial
fibrillation (AF) with an increased risk of stroke. Oral anticoagulants (AC)
dramatically reduce the risk of stroke but increase risk of major bleeding. As
a consequence, guidelines recommend a risk-based approach to anticoagula-
tion for AF. The CHADS2 score is the most widely used. In France,
thromboprophylaxis of patients with AF is followed up in primary care. This
study was to describe AF patients’ management by general practitioners
(GP).
Methods : This cross-sectional study analyzed the Longitudinal Patient
Database (LPD) which contains prescriptions, patients’ profiles and other
information collected by a representative sample of 1,200 GPs. Data from all
patients present in the database from July-2010 to June-2011, with a diagnosis
of AF and aged 18 and above were extracted. CHADS2 score based on 5 fea-
tures (HTA, age ≥75, diabetes, previous stroke, transient ischaemic attack or
systemic embolism, congestive heart failure or left ventricular dysfunction)
was calculated for all patients. According to ESC guidelines, no antithrom-
botic therapy is preferred for AF patients with CHADS2 score=0, aspirin or
oral AC is recommended with CHADS2 score=1 and chronic oral AC is rec-
ommended with a CHADS2 score ≥2.
Results : A total of 15,623 AF patients were identified. Mean age was 74.6
(±11.1) years old, 59.5% were men and mean CHADS2 score was 1.5 (±1.1).
Table1: Antithrombotic therapy according to CHADS2 score
Conclusion : In this large French patient database, in primary care
according to ESC guidelines, more than 40% of AF patients with a very low
risk of stroke (CHADS2=0) are over treated, while 45% of high risk patients
(CHADS2=2) are under-treated. Further analyses should be performed to
investigate the gap between clinical practice and guidelines.
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CHADS2
=0
=2638
CHADS2
=1
=5026
CHADS2
 ≥2
=7959
Total
=15623
Antithrombotic 
therapy
N 2638 5026 7959 1562
VKA* n (%) 1090 
(41.3%)
2460 
(48.9%)
4372 
(54.9%)
7922 
(50.7%)
Aspirin* n (%) 610 
(23.1%)
1079 
(21.5%)
1571 
(19.8%)
3260 
(20.9%)
None n (%) 938 
(35.5%)
1487 
(29.6%)
2016 
(25.3%)
4441 
(28.4%)
*Alone or associated
